Table 2. Clinical response of wild-KRAS mCRC patients treated with adjuvant cetuximab according to FCGR2A and FCGR3A polymorphisms.
| Genetic Model | Polymorphism | No. of patients | Objective response | Disease control | ||||
|---|---|---|---|---|---|---|---|---|
| CR+PR | SD+PD | P-value | CR+PR+SD | PD | P-value | |||
| FCGR2A H131R | No. | No. | No. | No. | ||||
| Co-dominant | HR vs. HH | 44/33 | 12/7 | 32/26 | 0.542 | 21/14 | 23/19 | 0.644 |
| RR vs. HH | 5/33 | 2/7 | 3/26 | 0.357* | 3/14 | 2/−19 | 0.461* | |
| Dominant | HR/RR vs. HH | 49/33 | 14/7 | 35/26 | 0.454 | 24/14 | 25/19 | 0.559 |
| Recessive | RR vs. HH/HR | 5/77 | 2/19 | 3/58 | 0.598* | 3/35 | 2/42 | 0.527* |
| Over-dominant | HR vs. HH/RR | 44/38 | 12/9 | 32/29 | 0.71 | 21/17 | 23/21 | 0.787 |
| Allele | R vs. H | 54 /110 | 16/26 | 38/84 | 0.409 | 27/49 | 27/61 | 0.51 |
| FCGR3A F158V | ||||||||
| Co-dominant | FV vs. FF | 25/49 | 5/14 | 20/35 | 0.425 | 10/24 | 15/25 | 0.463 |
| VV vs. FF | 8/49 | 2/14 | 6/35 | 0.835* | 4/24 | 4/25 | 0.957* | |
| Dominant | FV/VV vs. FF | 33/49 | 7/14 | 26/35 | 0.454 | 14/24 | 19/25 | 0.559 |
| Recessive | VV vs. FF/FV | 8/74 | 2/19 | 6/55 | 0.967* | 4/34 | 4/40 | 1.000* |
| Over-dominant | FV vs. FF/VV | 25/57 | 5/16 | 20/41 | 0.441 | 10/28 | 15/29 | 0.446 |
| Allele | V vs. F | 41/123 | 9/33 | 32/90 | 0.535 | 18/58 | 23/65 | 0.718 |
| FCGR combined | ||||||||
| H and F vs RR or VV | 69/13 | 17/4 | 52/9 | 0.642 | 31/7 | 38/6 | 0.554 | |
Abbreviation: mCRC: metastatic colorectal cancer; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease. P-value: result of chi-square test;
*
P-value: result of fisher's exact test.